viewHemoGenyx Pharmaceuticals

Hemogenyx Pharma Plc - Exercise of Warrants

RNS Number : 2057N
Hemogenyx Pharmaceuticals PLC
18 May 2020


Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")


Exercise of Warrants


Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that, pursuant to the receipt of a warrant exercise notice, it has issued and allotted 668,000 ordinary shares of 1p each in the Company at an exercise price of 5.25p per share for a total consideration of £35,070.

Application will be made for the new Ordinary Shares to be admitted to trading on the Official List of the UK Listing Authority by way of a Standard Listing ('Admission'). The Shares will rank pari passu in all respects with the existing shares. Admission is expected to occur on or around 22 May 2020.


Total Voting Rights

Following Admission, the Company will have 397,921,969 ordinary shares of £0.01 each in issue with voting rights. This figure may then be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.



Hemogenyx Pharmaceuticals plc


Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

[email protected]

Peter Redmond, Non-Executive Director

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: HemoGenyx Pharmaceuticals

Price: 5.9

Market: LSE
Market Cap: £25.58 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18